Syntaxin-binding protein STXBP5 inhibits endothelial exocytosis and promotes platelet secretion

Journal of Clinical Investigation

Volumn 124, Issue 10, 2014, Pages 4503-4516

  Zhu, Qiuyu ^a,b   Yamakuchi, Munekazu ^a,c   Ture, Sara ^a   De La Luz Garcia Hernandez, Maria ^a   Ko, Kyung Ae ^a   Modjeski, Kristina L ^a,b   LoMonaco, Michael B ^a   Johnson, Andrew D ^d   O'Donnell, Christopher J ^d,e   Takai, Yoshimi ^f   Morrell, Craig N ^a   Lowenstein, Charles J ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^c KAGOSHIMA UNIVERSITY   (Japan)

^d FRAMINGHAM HEART STUDY   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CELLUBREVIN; INSULIN; PADGEM PROTEIN; SNARE PROTEIN; SYNTAXIN; SYNTAXIN 4; SYNTAXIN BINDING PROTEIN 5; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN; ADAMTS13 PROTEIN, MOUSE; METALLOPROTEINASE; NERVE PROTEIN; STXBP5 PROTEIN, HUMAN; SYNAPTOBREVIN; TOMOSYN PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEEDING TIME; CAROTID ARTERY THROMBOSIS; CONTROLLED STUDY; ENDOTHELIAL EXOCYTOSIS; ENDOTHELIUM CELL; EXOCYTOSIS; FLUORESCENT ANTIBODY TECHNIQUE; GENE TRANSLOCATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; INSULIN RELEASE; MOUSE; NEUROTRANSMITTER RELEASE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN BLOOD LEVEL; PROTEIN INTERACTION; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE RELEASE REACTION; ANIMAL; AORTA; C57BL MOUSE; CYTOLOGY; ENDOTHELIUM; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; KNOCKOUT MOUSE; MALE; METABOLISM; MICROCIRCULATION; THROMBOCYTE; THROMBOSIS; UMBILICAL VEIN ENDOTHELIAL CELL;

ADAM PROTEINS; ANIMALS; AORTA; BLOOD PLATELETS; ENDOTHELIAL CELLS; ENDOTHELIUM; EXOCYTOSIS; GENE EXPRESSION REGULATION; HEK293 CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; METALLOENDOPEPTIDASES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROCIRCULATION; NERVE TISSUE PROTEINS; P-SELECTIN; QA-SNARE PROTEINS; R-SNARE PROTEINS; THROMBOSIS; VON WILLEBRAND FACTOR;

EID: 84907495473     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI71245     Document Type: Article

References (87)

1. Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med. 2008;359(9):938-949.
2. Wells PS, Forgie MA, Rodger MA. Treatment of venous thromboembolism. JAMA. 2014;311(7):717-728.
3. Farge D, et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost. 2013;11(1):56-70.
4. Wagner DD, Frenette PS. The vessel wall and its interactions. Blood. 2008;111(11):5271-5281.
5. Mackman N. Triggers, targets and treatments for thrombosis. Nature. 2008;451(7181):914-918.
6. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A. 1987;84(24):9265-9269.
7. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987;327(6122):524-526.
8. Marcus AJ, Broekman MJ, Pinsky DJ. COX inhibitors and thromboregulation. N Engl J Med. 2002;347(13):1025-1026.
9. Marcus AJ, et al. Role of CD39 (NTPDase-1) in thromboregulation, cerebroprotection, and cardioprotection. Semin Thromb Hemost. 2005;31(2):234-246.
10. Lowenstein CJ, Morrell CN, Yamakuchi M. Regulation of Weibel-Palade body exocytosis. Trends Cardiovasc Med. 2005;15(8):302-308.
11. Weibel ER, Palade GE. New cytoplasmic components in arterial endothelia. J Cell Biol. 1964;23:101-112.
12. Bergmeier W, Chauhan AK, Wagner DD. Glycoprotein Ibalpha and von Willebrand factor in primary platelet adhesion and thrombus formation: lessons from mutant mice. Thromb Haemost. 2008;99(2):264-270.
13. Wagner DD. The Weibel-Palade body: the storage granule for von Willebrand factor and P-selectin. Thromb Haemost. 1993;70(1):105-110.
14. Calvert JW, et al. Inhibition of N-ethylmaleimide-sensitive factor protects against myocardial ischemia/reperfusion injury. Circ Res. 2007;101(12):1247-1254.
15. Yamakuchi M, et al. HMG-CoA reductase inhibitors inhibit endothelial exocytosis and decrease myocardial infarct size. Circ Res. 2005;96(11):1185-1192.
16. Goodman DM, Burke AE, Livingston EH. JAMA patient page. Bleeding disorders. JAMA. 2012;308(14):1492.
17. Thompson SG, Kienast J, Pyke SD, Haverkate F, Van De Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med. 1995;332(10):635-641.
18. Spiel AO, Gilbert JC, Jilma B. von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes. Circulation. 2008;117(11):1449-1459.
19. Vischer UM. von Willebrand factor, endothelial dysfunction, and cardiovascular disease. J Thromb Haemost. 2006;4(6):1186-1193.
20. Jahn R, Sudhof TC. Membrane fusion and exocytosis. Annu Rev Biochem. 1999;68:863-911.
21. Rothman JE. Mechanisms of intracellular protein transport. Nature. 1994;372(6501):55-63.
22. Bajjalieh SM, Scheller RH. Synaptic vesicle proteins and exocytosis. Adv Second Messenger Phosphoprotein Res. 1994;29:59-79.
23. Sudhof TC. The synaptic vesicle cycle: a cascade of protein-protein interactions. Nature. 1995;375(6533):645-653.
24. Jahn R, Scheller RH. SNAREs - engines for membrane fusion. Nat Rev Mol Cell Biol. 2006;7(9):631-643.
25. Sudhof TC. The synaptic vesicle cycle revisited. Neuron. 2000;28(2):317-320.
26. Martens S, McMahon HT. Mechanisms of membrane fusion: disparate players and common principles. Nat Rev Mol Cell Biol. 2008;9(7):543-556.
27. 2+-dependent exocytosis. Biochim Biophys Acta. 2011;1813(5):1038-1044.
28. Jung JJ, Tiwari A, Inamdar SM, Thomas CP, Goel A, Choudhury A. Secretion of soluble vascular endothelial growth factor receptor 1 (sVEGFR1/sFlt1) requires Arf1, Arf6, and Rab11 GTPases. PLoS One. 2012;7(9):e44572.
29. Van Hooren KW, Van Agtmaal EL, Fernandez-Borja M, Van Mourik JA, Voorberg J, Bierings R. The Epac-Rap1 signaling pathway controls cAMP-mediated exocytosis of Weibel-Palade bodies in endothelial cells. J Biol Chem. 2012;287(29):24713-24720.
30. Yamakuchi M, et al. Exocytosis of endothelial cells is regulated by N-ethylmaleimide-sensitive factor. Methods Mol Biol. 2008;440:203-215.
31. Bierings R, et al. The interplay between the Rab27A effectors Slp4-a and MyRIP controls hormone-evoked Weibel-Palade body exocytosis. Blood. 2012;120(13):2757-2767.
32. Pulido IR, Nightingale TD, Darchen F, Seabra MC, Cutler DF, Gerke V. Myosin Va acts in concert with Rab27a and MyRIP to regulate acute von-Willebrand factor release from endothelial cells. Traffic. 2011;12(10):1371-1382.
33. Nightingale TD, Pattni K, Hume AN, Seabra MC, Cutler DF. Rab27a and MyRIP regulate the amount and multimeric state of VWF released from endothelial cells. Blood. 2009;113(20):5010-5018.
34. Kim KS, Park JY, Jou I, Park SM. Regulation of Weibel-Palade body exocytosis by alphasynuclein in endothelial cells. J Biol Chem. 2010;285(28):21416-21425.
35. Matsushita K, et al. Nitric oxide regulates exocytosis by S-nitrosylation of N-ethylmaleimidesensitive factor. Cell. 2003;115(2):139-150.
36. Ito T, Yamakuchi M, Lowenstein CJ. Thioredoxin increases exocytosis by denitrosylating N-ethylmaleimide-sensitive factor. J Biol Chem. 2011;286(13):11179-11184.
37. Huang J, Motto DG, Bundle DR, Sadler JE. Shiga toxin B subunits induce VWF secretion by human endothelial cells and thrombotic microangiopathy in ADAMTS13-deficient mice. Blood. 2010;116(18):3653-3659.
38. Liu F, Huang J, Sadler JE. Shiga toxin (Stx) 1B and Stx2B induce von Willebrand factor secretion from human umbilical vein endothelial cells through different signaling pathways. Blood. 2011;118(12):3392-3398.
39. Knipe L, et al. A revised model for the secretion of tPA and cytokines from cultured endothelial cells. Blood. 2010;116(12):2183-2191.
40. Into T, et al. Pathogen recognition by Toll-like receptor 2 activates Weibel-Palade body exocytosis in human aortic endothelial cells. J Biol Chem. 2007;282(11):8134-8141.
41. Bhatia R, Matsushita K, Yamakuchi M, Morrell CN, Cao W, Lowenstein CJ. Ceramide triggers Weibel-Palade body exocytosis. Circ Res. 2004;95(3):319-324.
42. Matsushita K, Morrell CN, Lowenstein CJ. Sphingosine 1-phosphate activates Weibel-Palade body exocytosis. Proc Natl Acad Sci U S A. 2004;101(31):11483-11487.
43. Jeong Y, et al. Aldosterone activates endothelial exocytosis. Proc Natl Acad Sci U S A. 2009;106(10):3782-3787.
44. Yamakuchi M, et al. Antibody to human leukocyte antigen triggers endothelial exocytosis. Proc Natl Acad Sci U S A. 2007;104(4):1301-1306.
45. Smith NL, et al. Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium. Circulation. 2010;121(12):1382-1392.
46. Antoni G, et al. Combined analysis of three genome-wide association studies on vWF and FVIII plasma levels. BMC Med Genet. 2011;12:102.
47. Van Loon JE, et al. Effect of genetic variations in syntaxin-binding protein-5 and syntaxin-2 on von Willebrand factor concentration and cardiovascular risk. Circ Cardiovasc Genet. 2010;3(6):507-512.
48. Smith NL, et al. Genetic variation associated with plasma von Willebrand factor levels and the risk of incident venous thrombosis. Blood. 2011;117(22):6007-6011.
49. Fujita Y, et al. Tomosyn: a syntaxin-1-binding protein that forms a novel complex in the neurotransmitter release process. Neuron. 1998;20(5):905-915.
50. Yokoyama S, Shirataki H, Sakisaka T, Takai Y. Three splicing variants of tomosyn and identification of their syntaxin-binding region. Biochem Biophys Res Commun. 1999;256(1):218-222.
51. Groffen AJ, Jacobsen L, Schut D, Verhage M. Two distinct genes drive expression of seven tomosyn isoforms in the mammalian brain, sharing a conserved structure with a unique variable domain. J Neurochem. 2005;92(3):554-568.
52. Pobbati AV, Razeto A, Boddener M, Becker S, Fasshauer D. Structural basis for the inhibitory role of tomosyn in exocytosis. J Biol Chem. 2004;279(45):47192-47200.
53. Hatsuzawa K, Lang T, Fasshauer D, Bruns D, Jahn R. The R-SNARE motif of tomosyn forms SNARE core complexes with syntaxin 1 and SNAP-25 and down-regulates exocytosis. J Biol Chem. 2003;278(33):31159-31166.
54. Masuda ES, Huang BC, Fisher JM, Luo Y, Scheller RH. Tomosyn binds t-SNARE proteins via a VAMP-like coiled coil. Neuron. 1998;21(3):479-480.
55. Yizhar O, et al. Multiple functional domains are involved in tomosyn regulation of exocytosis. J Neurochem. 2007;103(2):604-616.
56. Sakisaka T, et al. Dual inhibition of SNARE complex formation by tomosyn ensures controlled neurotransmitter release. J Cell Biol. 2008;183(2):323-337.
57. Yizhar O, et al. Tomosyn inhibits priming of large dense-core vesicles in a calciumdependent manner. Proc Natl Acad Sci U S A. 2004;101(8):2578-2583.
58. Yamamoto Y, et al. The tail domain of tomosyn controls membrane fusion through tomosyn displacement by VAMP2. Biochem Biophys Res Commun. 2010;399(1):24-30.
59. Williams AL, et al. Structural and functional analysis of tomosyn identifies domains important in exocytotic regulation. J Biol Chem. 2011;286(16):14542-14553.
60. 2+-dependent exocytosis of neurotransmitter. J Cell Biol. 2005;170(7):1113-1125.
61. Gladycheva SE, et al. Receptor-mediated regulation of tomosyn-syntaxin 1A interactions in bovine adrenal chromaffin cells. J Biol Chem. 2007;282(31):22887-22899.
62. Mcever RP, Beckstead JH, Moore KL, Marshallcarlson L, Bainton DF. GMP-140, a platelet α-granule membrane protein, is also synthesized by vascular endothelial cells and is localized in Weibel-Palade bodies. J Clin Invest. 1989;84(1):92-99.
63. Hagedorn I, Vogtle T, Nieswandt B. Arterial thrombus formation. Novel mechanisms and targets. Hamostaseologie. 2010;30(3):127-135.
64. Stoll G, Kleinschnitz C, Nieswandt B. Molecular mechanisms of thrombus formation in ischemic stroke: novel insights and targets for treatment. Blood. 2008;112(9):3555-3562.
65. Falanga A, Marchetti M, Vignoli A, Balducci D. Clotting mechanisms and cancer: implications in thrombus formation and tumor progression. Clin Adv Hematol Oncol. 2003;1(11):673-678.
66. Fu J, Naren AP, Gao X, Ahmmed GU, Malik AB. Protease-activated receptor-1 activation of endothelial cells induces protein kinase Cα-dependent phosphorylation of syntaxin 4 and Munc18c: role in signaling p-selectin expression. J Biol Chem. 2005;280(5):3178-3184.
67. Valentijn KM, Sadler JE, Valentijn JA, Voorberg J, Eikenboom J. Functional architecture of Weibel-Palade bodies. Blood. 2011;117(19):5033-5043.
68. 2+-dependent neurotransmitter release through its N-terminal WD40 repeats. J Biol Chem. 2010;285(52):40943-40955.
69. Savage B, Ginsberg MH, Ruggeri ZM. Influence of fibrillar collagen structure on the mechanisms of platelet thrombus formation under flow. Blood. 1999;94(8):2704-2715.
70. Van Loon JE, Sanders YV, De Wee EM, Kruip MJ, De Maat MP, Leebeek FW. Effect of genetic variation in STXBP5 and STX2 on von Wille brand factor and bleeding phenotype in type 1 von Willebrand disease patients. PLoS One. 2012;7(7):e40624.
71. McEwen JM, Madison JM, Dybbs M, Kaplan JM. Antagonistic regulation of synaptic vesicle priming by Tomosyn and UNC-13. Neuron. 2006;51(3):303-315.
72. Grosshans BL, et al. The yeast lgl family member Sro7p is an effector of the secretory Rab GTPase Sec4p. J Cell Biol. 2006;172(1):55-66.
73. Hattendorf DA, Andreeva A, Gangar A, Brennwald PJ, Weis WI. Structure of the yeast polarity protein Sro7 reveals a SNARE regulatory mechanism. Nature. 2007;446(7135):567-571.
74. Schwab Y, Mouton J, Chasserot-Golaz S, Marty I, Maulet Y, Jover E. Calcium-dependent translocation of synaptotagmin to the plasma membrane in the dendrites of developing neurones. Mol Brain Res. 2001;96(1-2):1-13.
75. Tang J, Maximov A, Shin OH, Dai H, Rizo J, Sudhof TC. A complexin/synaptotagmin 1 switch controls fast synaptic vesicle exocytosis. Cell. 2006;126(6):1175-1187.
76. Seven AB, Brewer KD, Shi L, Jiang QX, Rizo J. Prevalent mechanism of membrane bridging by synaptotagmin-1. Proc Natl Acad Sci U S A. 2013;110(34):E3243-E3E52.
77. Xu JJ, Brewer KD, Perez-Castillejos R, Rizo J. Subtle Interplay between synaptotagmin and complexin binding to the SNARE complex. J Mol Biol. 2013;425(18):3461-3475.
78. Blagoveshchenskaya AD, Hannah MJ, Allen S, Cutler DF. Selective and signal-dependent recruitment of membrane proteins to secretory granules formed by heterologously expressed von Willebrand factor. Mol Biol Cell. 2002;13(5):1582-1593.
79. Giblin JP, Hewlett LJ, Hannah MJ. Basal secretion of von Willebrand factor from human endothelial cells. Blood. 2008;112(4):957-964.
80. Cheviet S, et al. Tomosyn-1 is involved in a postdocking event required for pancreatic β-cell exocytosis. J Cell Sci. 2006;119(pt 14):2912-2920.
81. Kanaji S, Fahs SA, Shi Q, Haberichter SL, Montgomery RR. Contribution of platelet vs. endothelial VWF to platelet adhesion and hemostasis. J Thromb Haemost. 2012;10(8):1646-1652.
82. Morrell CN, Matsushita K, Lowenstein CJ. A novel inhibitor of N-ethylmaleimide-sensitive factor decreases leukocyte trafficking and peritonitis. J Pharmacol Exp Ther. 2005;314(1):155-161.
83. Dayananda KM, Gogia S, Neelamegham S. Escherichia coli-derived von Willebrand factor-A2 domain fluorescence/Forster resonance energy transfer proteins that quantify ADAMTS13 activity. Anal Biochem. 2011;410(2):206-213.
84. Widberg CH, Bryant NJ, Girotti M, Rea S, James DE. Tomosyn interacts with the t-SNAREs syntaxin4 and SNAP23 and plays a role in insulinstimulated GLUT4 translocation. J Biol Chem. 2003;278(37):35093-35101.
85. Morrell CN, et al. Glutamate mediates platelet activation through the AMPA receptor. J Exp Med. 2008;205(3):575-584.
86. Owens AP, et al. Towards a standardization of the murine ferric chloride-induced carotid arterial thrombosis model. J Thromb Haemost. 2011;9(9):1862-1863.
87. Eckly A, et al. Mechanisms underlying FeCl3-induced arterial thrombosis. J Thromb Haemost. 2011;9(4):779-789.